Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Saillard

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Annals of Hematology|February 24, 2020
Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcomeB Bouchacourt, M A Hospital, C Zemmour, et al.
Acta Anaesthesiologica Scandinavica|January 10, 2018
Early prognostic factors in septic shock cancer patients: a prospective study with a proteomic approachD Mokart, C Saillard, C Zemmour, et al.
European Journal of Haematology|November 30, 2023
Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patientsC Petit, C Saillard, B Mohty, et al.
Blood Cancer Journal|June 4, 2020
A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility studyA Collignon, M A Hospital, C Montersino, et al.
Nature Communications|July 2, 2025
Deep learning assessment of metastatic relapse risk from digitized breast cancer histological slidesI Garberis, V Gaury, C Saillard, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Annals of Hematology|February 24, 2020
Post-remission therapy of adults aged 60 and older with acute myeloid leukemia in first complete remission: role of treatment intensity on the outcomeB Bouchacourt, M A Hospital, C Zemmour, et al.
Acta Anaesthesiologica Scandinavica|January 10, 2018
Early prognostic factors in septic shock cancer patients: a prospective study with a proteomic approachD Mokart, C Saillard, C Zemmour, et al.
European Journal of Haematology|November 30, 2023
Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patientsC Petit, C Saillard, B Mohty, et al.
Blood Cancer Journal|June 4, 2020
A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility studyA Collignon, M A Hospital, C Montersino, et al.
Nature Communications|July 2, 2025
Deep learning assessment of metastatic relapse risk from digitized breast cancer histological slidesI Garberis, V Gaury, C Saillard, et al.
Pageof 6